180 related articles for article (PubMed ID: 22217438)
1. Asenapine: a clinical overview.
Potkin SG
J Clin Psychiatry; 2011; 72 Suppl 1():14-8. PubMed ID: 22217438
[TBL] [Abstract][Full Text] [Related]
2. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
[TBL] [Abstract][Full Text] [Related]
3. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
Kemp DE; Zhao J; Cazorla P; Landbloom RP; Mackle M; Snow-Adami L; Szegedi A
J Clin Psychiatry; 2014 Mar; 75(3):238-45. PubMed ID: 24499969
[TBL] [Abstract][Full Text] [Related]
4. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Citrome L
Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
[TBL] [Abstract][Full Text] [Related]
5. Asenapine: a new antipsychotic option.
Henry JM; Fuller MA
J Pharm Pract; 2011 Oct; 24(5):447-51. PubMed ID: 22156709
[TBL] [Abstract][Full Text] [Related]
6. Asenapine-Induced Acute Dystonia in an Adolescent Male.
Bhuyan D; Ghosh S; Bhattacharya A; Praharaj SK
J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):955-956. PubMed ID: 27154343
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
[TBL] [Abstract][Full Text] [Related]
8. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.
Kane JM; Mackle M; Snow-Adami L; Zhao J; Szegedi A; Panagides J
J Clin Psychiatry; 2011 Mar; 72(3):349-55. PubMed ID: 21367356
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the clinical efficacy of asenapine in schizophrenia.
Minassian A; Young JW
Expert Opin Pharmacother; 2010 Aug; 11(12):2107-15. PubMed ID: 20642375
[TBL] [Abstract][Full Text] [Related]
10. Asenapine review, part II: clinical efficacy, safety and tolerability.
Citrome L
Expert Opin Drug Saf; 2014 Jun; 13(6):803-30. PubMed ID: 24793161
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.
Schoemaker J; Stet L; Vrijland P; Naber D; Panagides J; Emsley R
Pharmacopsychiatry; 2012 Jul; 45(5):196-203. PubMed ID: 22454251
[TBL] [Abstract][Full Text] [Related]
12. Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorder.
Med Lett Drugs Ther; 2010 Feb; 52(1331):9-10. PubMed ID: 20216523
[No Abstract] [Full Text] [Related]
13. Allergic reactions and sudden death with asenapine.
Masters KJ
J Clin Psychiatry; 2012 May; 73(5):720; author reply 720-1. PubMed ID: 22697198
[No Abstract] [Full Text] [Related]
14. Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice.
Fagiolini A; Forgione RN; Morana B; Maccari M; Goracci A; Bossini L; Pellegrini F; Cuomo A; Casamassima F
Expert Opin Pharmacother; 2013 Mar; 14(4):489-504. PubMed ID: 23356509
[TBL] [Abstract][Full Text] [Related]
15. Asenapine.
Weber J; McCormack PL
CNS Drugs; 2009 Sep; 23(9):781-92. PubMed ID: 19689168
[TBL] [Abstract][Full Text] [Related]
16. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
Landbloom R; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
CNS Spectr; 2017 Aug; 22(4):333-341. PubMed ID: 27821210
[TBL] [Abstract][Full Text] [Related]
17. Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review.
Stepanova E; Grant B; Findling RL
Paediatr Drugs; 2018 Apr; 20(2):121-134. PubMed ID: 29170943
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.
Kinoshita T; Bai YM; Kim JH; Miyake M; Oshima N
Psychopharmacology (Berl); 2016 Jul; 233(14):2663-74. PubMed ID: 27271087
[TBL] [Abstract][Full Text] [Related]
19. Asenapine: a clinical review of a second-generation antipsychotic.
Stoner SC; Pace HA
Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
[TBL] [Abstract][Full Text] [Related]
20. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.
Chapel S; Hutmacher MM; Haig G; Bockbrader H; de Greef R; Preskorn SH; Lalonde RL
J Clin Pharmacol; 2009 Nov; 49(11):1297-308. PubMed ID: 19843656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
